reports
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A ...
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Derma Sciences, Inc. (Nasdaq: DSCI) (“Derma Sciences” or the “Company”) relating to the proposed buyout of Derma Sciences by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma Sciences common shareholders will receive $7 per share, while holders of S...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Derma Sciences, Inc. (Nasdaq: DSCI) (“Derma Sciences” or the “Company”) relating to the proposed buyout of Derma Sciences by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma Sciences common shareholders will receive $7 per share, while holders of S...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A ...
DERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Bri...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Derma Sciences, Inc. (“Derma”) (NasdaqCM: DSCI) concerning the acquisition by Integra LifeSciences Holdings Corporation. Under the terms of the agreement, Derma’s common shareholders will only receive $7.00 per Derma share owned. This consideration is significantly lower than at least one analyst’s estimated value of $8.50 per share. Holders of Derma’s Series A Co...
Derma Sciences Buys MEDIHONEY® Brand From Long-Term Partner
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the MEDIHONEY® brand and related intellectual property and goodwill from its long-term partner, New Zealand-based Comvita Limited. Consideration is an upfront payment of $13.25 million in cash, with an additional $5.0 million potentially payable in the form of an earn-out upon achievement of future annual sales milestones. Prior to the acquisition, Derma Sci...
DERMA SCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announc...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Derma Sciences, Inc. (NASDAQ CM: DSCI)? Did you purchase any of your shares prior to January 11, 2017? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Derma Sciences, Inc. (“Derma Sciences” or the “Company”) (NASDAQ CM:...
Derma Sciences to Be Acquired by Integra LifeSciences for $7.00 Per Sh...
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has signed a definitive agreement whereby Derma Sciences will be acquired by Integra LifeSciences Holdings Corporation (Nasdaq: IART) for $7.00 per share of common stock in cash, or a total of approximately $204 million, and $32.00 per share for its outstanding shares of Series A Convertible Preferred Stock and $48.00 per share for its Series B Convertible Preferred Stoc...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Derma Sciences to Present at the Canaccord Genuity Medical Technologie...
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and Interim Principal Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17th at 10:30 a.m. Eastern time. The conference is being held at the Westin Grand Central Hotel in New York City. To listen to the presentation, investors may visit the inves...
Derma Sciences Reports 2016 Third Quarter Financial Results
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and nine months ended September 30, 2016. Highlights of the third quarter of 2016 and recent weeks include: Completed the sale of the First Aid Division (FAD) including inventory for $9.7 million in cash and a $2.7 million promissory note Completed the acquisition of BioD, LLC (BioD), furthering the...
Derma Sciences to Hold Third Quarter Financial Results Conference Call...
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on November 10, 2016 to discuss the financial results for the third quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones. The conference call is scheduled to begin at 11:00 a.m. (Eastern Time). The results will be released before the opening of the market that same ...
Derma Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Co...
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and Interim Principal Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27th at 8:30 a.m. Eastern time. The program includes a formal presentation followed by a “fireside chat.” The conference is being held at the Sofitel New York in New York City. To listen t...
Update: New growth drivers offsetting temporary issues
Derma Sciences’ Q1 featured higher revenue and a lower loss than we had forecast. Advanced Wound Care (AWC, sales +17%) nearly offset the well-flagged softness in Traditional Wound Care (TWC, sales -15%), while operating costs were reined in. We leave our forecasts unchanged, leaving potential upside to our forecasts if MEDIHONEY sales to Medicare soon resume. Our DCF valuation is $320m.
Update: Picking up pace
Derma Sciences delivered a robust Q414 with rebounding sales growth but slowing cost growth. Based on lower overhead and R&D costs, we have tempered our forecast losses 2015-16e and our DCF-based valuation has been raised from $312m to $320m. Accelerated recruitment in the ongoing diabetic foot ulcer trials (DSC127) and improved cost absorption in Advanced Wound Care may lead to profitability as of 2018.
Outlook: Pure play wound care with long-term potential
Derma Sciences offers novel treatments for the fast-growing wound care market. After a challenging 2014, we see recovering sales growth but deeper losses in 2015-17e due to investment in sales and R&D. Positive results from ongoing diabetic foot ulcer trials (DSC127) and improved cost absorption in AWC may lead to profitability as of 2018. We value the stock at $12.3 based on DCF, with DSC127 as the key driver.
Update: Transient AWC issues do not detract
Derma Sciences has faced near-term challenges to its advanced wound care (AWC) franchise in Q213, affecting the sales growth of MEDIHONEY and TCC-EZ. This has led us to forecast deeper losses in 2014-15 and trim our valuation to $13.4 from $15.6 per share. However, its AWC products still have strong growth prospects and we believe the current share price attributes no probability to DSC127 successfully reaching the market.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.